A detailed history of Tokio Marine Asset Management CO LTD transactions in Abb Vie Inc. stock. As of the latest transaction made, Tokio Marine Asset Management CO LTD holds 50,119 shares of ABBV stock, worth $8.27 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares
50,119
Previous 46,815 7.06%
Holding current value
$8.27 Million
Previous $8.03 Million 23.27%
% of portfolio
0.44%
Previous 0.39%

Shares

35 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$163.84 - $199.33 $541,327 - $658,586
3,304 Added 7.06%
50,119 $9.9 Million
Q2 2024

Jul 26, 2024

BUY
$154.79 - $180.76 $328,000 - $383,030
2,119 Added 4.74%
46,815 $8.03 Million
Q1 2024

May 02, 2024

BUY
$159.82 - $182.1 $625,215 - $712,375
3,912 Added 9.59%
44,696 $8.14 Million
Q4 2023

Feb 02, 2024

BUY
$137.6 - $154.97 $260,476 - $293,358
1,893 Added 4.87%
40,784 $6.32 Million
Q3 2023

Nov 02, 2023

BUY
$133.59 - $154.65 $319,012 - $369,304
2,388 Added 6.54%
38,891 $5.8 Million
Q2 2023

Jul 28, 2023

BUY
$132.51 - $164.9 $261,177 - $325,017
1,971 Added 5.71%
36,503 $4.92 Million
Q1 2023

May 11, 2023

BUY
$144.61 - $166.54 $603,457 - $694,971
4,173 Added 13.75%
34,532 $5.5 Million
Q4 2022

Jan 26, 2023

BUY
$138.31 - $165.87 $391,417 - $469,412
2,830 Added 10.28%
30,359 $0
Q3 2022

Nov 10, 2022

BUY
$134.21 - $153.93 $342,369 - $392,675
2,551 Added 10.21%
27,529 $3.7 Million
Q2 2022

Aug 09, 2022

BUY
$137.62 - $174.96 $575,802 - $732,032
4,184 Added 20.12%
24,978 $3.83 Million
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $483,574 - $599,980
3,664 Added 21.39%
20,794 $3.37 Million
Q4 2021

Jan 26, 2022

BUY
$107.43 - $135.93 $68,003 - $86,043
633 Added 3.84%
17,130 $2.32 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $234,292 - $265,957
2,202 Added 15.4%
16,497 $1.78 Million
Q2 2021

Aug 12, 2021

BUY
$105.21 - $117.21 $103,631 - $115,451
985 Added 7.4%
14,295 $1.61 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $266,593 - $293,487
2,606 Added 24.35%
13,310 $1.44 Million
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $45,557 - $61,507
566 Added 5.58%
10,704 $1.15 Million
Q3 2020

Nov 09, 2020

BUY
$85.91 - $100.83 $101,116 - $118,676
1,177 Added 13.13%
10,138 $888,000
Q2 2020

Aug 07, 2020

BUY
$73.37 - $98.18 $169,044 - $226,206
2,304 Added 34.61%
8,961 $880,000
Q1 2020

May 12, 2020

BUY
$64.5 - $97.79 $88,816 - $134,656
1,377 Added 26.08%
6,657 $507,000
Q4 2019

Feb 14, 2020

BUY
$72.13 - $90.25 $35,992 - $45,034
499 Added 10.44%
5,280 $467,000
Q3 2019

Oct 29, 2019

BUY
$62.98 - $75.72 $42,700 - $51,338
678 Added 16.52%
4,781 $362,000
Q2 2019

Jul 25, 2019

BUY
$65.7 - $83.98 $28,513 - $36,447
434 Added 11.83%
4,103 $298,000
Q1 2019

Apr 25, 2019

BUY
$77.14 - $90.79 $40,961 - $48,209
531 Added 16.92%
3,669 $296,000
Q4 2018

Feb 04, 2019

BUY
$77.85 - $96.01 $33,319 - $41,092
428 Added 15.79%
3,138 $289,000
Q3 2018

Oct 23, 2018

SELL
$88.91 - $98.84 $104,202 - $115,840
-1,172 Reduced 30.19%
2,710 $256,000
Q2 2018

Jul 18, 2018

SELL
$89.78 - $106.23 $182,522 - $215,965
-2,033 Reduced 34.37%
3,882 $360,000
Q1 2018

May 03, 2018

SELL
$92.01 - $123.21 $301,424 - $403,635
-3,276 Reduced 35.64%
5,915 $560,000
Q4 2017

Feb 05, 2018

SELL
$89.56 - $98.21 $303,250 - $332,539
-3,386 Reduced 26.92%
9,191 $889,000
Q3 2017

Oct 30, 2017

SELL
$69.85 - $89.22 $277,514 - $354,471
-3,973 Reduced 24.01%
12,577 $1.12 Million
Q2 2017

Jan 11, 2018

SELL
N/A
-5,799 Reduced 25.95%
16,550 $1.2 Million
Q1 2017

Jan 11, 2018

SELL
N/A
-7,044 Reduced 23.96%
22,349 $1.46 Million
Q4 2016

Jan 11, 2018

SELL
N/A
-11,074 Reduced 27.37%
29,393 $1.84 Million
Q3 2016

Jan 11, 2018

SELL
N/A
-5,758 Reduced 12.46%
40,467 $2.55 Million
Q2 2016

Jan 11, 2018

SELL
N/A
-1,683 Reduced 3.51%
46,225 $2.86 Million
Q1 2016

Jan 11, 2018

BUY
N/A
47,908
47,908 $2.74 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $292B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Tokio Marine Asset Management CO LTD Portfolio

Follow Tokio Marine Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tokio Marine Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Tokio Marine Asset Management CO LTD with notifications on news.